SSG
JBIO

Summit Securities Group’s Jade Biosciences JBIO Stock Holding History

Summit Securities Group’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,135
Closed -$15.9K – 1159
2026
Q1 		$15.9K Buy
+1,135
New +$16.4K ﹤0.01% 568

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Summit Securities Group's JBIO Position: Q2 2026 in Review

Summit Securities Group sold out of Jade Biosciences (JBIO) in Q2 2026, closing a stake of 1,135 shares — an estimated $15.9K sold.

Summit Securities Group first reported a position in JBIO in Q1 2026 and held it in 1 quarter. The position peaked at $15.9K in Q1 2026. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Summit Securities Group reported no remaining Jade Biosciences position as of Q2 2026 after selling out during the quarter.
  • Summit Securities Group sold 1,135 Jade Biosciences shares in Q2 2026, an estimated $15.9K.
  • Summit Securities Group first reported a position in Jade Biosciences in Q1 2026 and held it in 1 quarter.
  • Summit Securities Group's Jade Biosciences position peaked at $15.9K in Q1 2026.
  • 154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.